662P Pembrolizumab (pembro) monotherapy as first-line therapy in advanced non–clear cell renal cell carcinoma (nccRCC): Results after a minimum of 34 months of follow-up from KEYNOTE-427 cohort B
Abstract
In the single-arm, open-label, phase II KEYNOTE-427 study, first-line pembro monotherapy showed antitumor activity in nccRCC (cohort B) (NCT02853344). We present updated efficacy and safety results after a minimum of 34.1 mo of follow-up for pts with...
Paper Details
Title
662P Pembrolizumab (pembro) monotherapy as first-line therapy in advanced non–clear cell renal cell carcinoma (nccRCC): Results after a minimum of 34 months of follow-up from KEYNOTE-427 cohort B
Published Date
Sep 1, 2021
Journal
Volume
32
Pages
S687 - S687
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History